Targets › ADRB3
16 programs from 16 companies in 95 trials: 37 Phase 4, 27 Phase 2, 16 Phase 1, 15 Phase 3; Neurology, Gastroenterology, Oncology; next expected readout Dec 2026.
G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, leading to either activation or inhibition of adenylate cyclase and cAMP-dependent pathway, respectively. The rank order of potency for physiological agonists is norepinephrine > epinephrine. (UniProt, P13945)
Open in Phaseline: the race on ADRB3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| King's College Hospital NHS Trust | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cirrhosis, Liver | Dec 2026 |
| Hospital Sirio-Libanes | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cancer | May 2027 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cirrhotic Cardiomyopathy | Jan 2029 |
| Taipei Veterans General Hospital, Taiwan | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Hepatocellular Carcinoma (HCC); Cirrhosis | Oct 2030 |
| University of Rochester | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Heart Failure With Reduced Ejection Fraction (HFrEF) | Jun 2031 |
| Chinese University of Hong Kong | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Portal Hypertension | Jul 2031 |
| Bispebjerg Hospital | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Acute Myocardial Infarction | Dec 2035 |
| SWOG Cancer Research Network | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 3 | Cardiotoxicity | Jun 2031 |
| Ain Shams University | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 3 | Cardiotoxicity | – |
| Astellas | mirabegron Beta-3 adrenergic receptor agonist | ADRB3 | Phase 3 | Neurogenic Detrusor Overactivity; Overactive Bladder Syndrome; Effect of Drug; Urinary Bladder, Overactive … | – |
| Urovant Sciences | Vibegron Beta-3 adrenergic receptor agonist | ADRB3 | Phase 2 | Neurogenic Detrusor Overactivity; Obesity | Mar 2030 |
| Sherief Abd-Elsalam | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | Esophageal Varices | Dec 2030 |
| Michele Tagliati, MD | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | REM Sleep Behavior Disorder | – |
| Cedars-Sinai Medical Center | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | REM Sleep Behavior Disorder | – |
| Mansoura University | carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 1 | TBI Traumatic Brain Injury | – |
Nicotine Dependence (3) Cardiotoxicity (2) Psoriasis Vulgaris (2) Cytomegalovirus (CMV) (2) REM Sleep Behavior Disorder (2) Neurogenic Detrusor Overactivity (2) Urgency Urinary Incontinence (2) Urinary Incontinence in Children (2) Hepatocellular Carcinoma (HCC) (1) Cirrhosis (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1) Portal Hypertension (1)
small molecule (16)
Taipei Veterans General Hospital, Taiwan (1) University of Rochester (1) Chinese University of Hong Kong (1) Ain Shams University (1) King's College Hospital NHS Trust (1) SWOG Cancer Research Network (1) Post Graduate Institute of Medical Education and Research, Chandigarh (1) University of California, San Francisco (1) Hospital Sirio-Libanes (1) Mansoura University (1) Michele Tagliati, MD (1) Cedars-Sinai Medical Center (1) Bispebjerg Hospital (1) Sherief Abd-Elsalam (1) Urovant Sciences (1) Astellas (1)
ADRB2 (14) ADRB1 (13) ADRA1A (13) ADRA1D (13) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.